Certara, Inc.
CERTHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframePart of the healthcare sector, Certara, Inc. (CERT) is listed under Health Information Services. With a market capitalization of $1.58B, it sits in small-cap territory. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes.
Market Cap
$1.58B
Beta
1.43
P/E (TTM)
—
P/E (Fwd)
26.33
EPS (TTM)
$-0.14
EPS (Fwd)
$0.39
ROE
-2.2%
ROA
0.8%
Cash
$184.9M
Total Debt
$301.9M
Free CF
$62.6M
52W Change
-18.4%
Annual Financials
Cash vs Debt
Where CERT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CERT finished 35.78% above its 150-day moving average ($6.96) and 31.07% above its 200-day moving average ($7.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CERT overbought or oversold?
At the October 20, 2026 close, CERT's RSI(14) was 52.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Certara, Inc. carries $301.9M in total debt against $184.9M in cash reserves — debt is roughly 1.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $62.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -2.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $335.6M (2022) to $418.8M (2025), reflecting a 25% increase over the period.
As with any equity investment, CERT carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing CERT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.